SONN Short EntryI went short yesterday after-hours at .95 at the 1.00 level. I set a Target order at .81. The target was hit today.
0%
0%
0%
0%
0%
−64.64USD
−29.722MUSD
349.943KUSD
1.751M
About Sonnet BioTherapeutics Holdings, Inc.
Sector
Industry
CEO
Pankaj Mohan
Website
Headquarters
Princeton
Employees
12
Founded
2011
ISIN
US83548R3030
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded in 2011 and is headquartered in Princeton, NJ.
SONN +100%Easiest 2x I've seen in a very long time. Confidence level of gaining 100% in the near term is close to 100%. I wouldn't get too greedy holding long on this one. If you zoom out, it's eternal death. Get in and get out.
$SONN A Pillar For Immuno OncologySome drugs address specific illnesses, while others enhance the pharmacokinetic responses of other drugs, which basically means that it assists other drugs. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN)’s FHAB™ compound does both by causing swelling around tumors which assists in the immune r
SONN im not sure highly doubt it but if it were to happen there everyones into this, these things just melt away, itll cetrainly go lower, but if it was to continue bouncing, here is your target, ggs
SONN 1W test
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The compan
SONN 15Min Scalpers editiontest
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The compa
Expected to be spiked next couple of days/weeksRSI @ all time frame lower all the time and additional volume expected soon.
waiting for good news and performance.
Good luck
SONN Technical Analysis 🧙Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
